CompoAtlas

A.Vogel VeganOmega 3

Natural health product licensed in Canada

Licence holder
Bioforce Canada Inc.
NPN or DIN-HM
80062614
Status
Active licence
Licence date
10 July 2015
Revision date
15 August 2024
Form
Capsule
Route of administration
Orale
Application type
Officinale

If this product were sold in France

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Schizochytrium spp.

Source : Schizochytrium spp. - Whole

Potency : 1.9 milligramme Eicosapentaenoic acid

214.29 milligrammeNot calculated
Schizochytrium spp.

Source : Schizochytrium spp. - Whole

Potency : 75 milligramme Docosahexaenoic acid

Not specifiedNot calculated
Linum usitatissimum

Source : Linum usitatissimum - Graine

Potency : 200 milligramme alpha-Linolenic acid

400 milligrammeNot calculated

Non-medicinal ingredients

Carraghénine, Huile essentielle de Menthe Poivrée, RRR-alpha-tocophérol, Lécithine, Palmitate d'ascorbyle, Extrait de romarin, Amidon alimentaire, modifié, Glycérol, Eau

PopulationAgeQuantity per servingFrequency
Adultesminimum: 18 years2 Capsule2 Tous les jours
Adultesminimum: 18 years2 Capsule1 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

Source of omega-3 fatty acid for the maintenance of good health. Helps support/maintain eye health/function. Helps support/maintain visual health/function. Helps support/ maintain cognitive health. Helps support/maintain brain function. Helps support/maintain (normal) heart/ cardiovascular health.

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

Source

Official Health Canada record, licence 80062614

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Linum usitatissimum
    Read the warning, when it applies and the studies cited

    FLAXSEED - LINUM USITATISSIMUM

    Route of administration: Oral

    Cautions and warnings

    Applies to products providing 5 g or more of flaxseed per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician immediately if you experience chest pain, vomiting, or difficulty swallowing or breathing after taking this product (EMA 2015).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes or a lazy bowel (EMA 2015; ESCOP 2003).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Laxative; Promotion of bowel movement; Constipation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (Pray 2006; Repchinsky 2002).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Applies to products providing 5 g or more of flaxseed per day.

    Do not use if you have difficulty swallowing (EMA 2015; ESCOP 2003).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (EMA 2015; Gardner and McGuffin 2013; Brinker 2010; ESCOP 2003).

    4 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (EMA 2015; León et al. 2003).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 26 July 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

Photograph the packaging

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2024. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line